The FY2025 (Dec) proxy of Humacyte names 17 peer companies for pay. Among Humacyte and these peers, CEO pay was 7th highest of 12 and total shareholder return was 9th highest of 12.
7th highest of 12in Humacyte and its pay peers, FY2025 (Dec) by CEO pay:
$2.4M$33.3M
9th highest of 12in Humacyte and its pay peers, FY2025 (Dec) by total shareholder return:
$18$487
Pay peer group, FY2025 (Dec) proxy
| Scholar Rock Holding | ||
| Cogent Biosciences | ||
| Arcutis Biotherapeutics | ||
| Vera Therapeutics | ||
| Tarsus Pharmaceuticals | ||
| Anaptysbio | ||
| Kura Oncology | ||
| Relay Therapeutics | ||
| Regenxbio | ||
| Rocket Pharmaceuticals | ||
| Editas Medicine | ||
| CVRx, Inc. | Not disclosed | Not disclosed |
| Day One Biopharma, Inc. | Not disclosed | Not disclosed |
| Maxcyte | Not disclosed | Not disclosed |
| Omeros | Not disclosed | Not disclosed |
| PureTech Health plc | Not disclosed | Not disclosed |
| Syndax Pharmaceuticals | Not disclosed | Not disclosed |
17 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.